PRFX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Prf Technologies Ltd 's Cash & cash equivalent grew by 24.99 % in the Q4 2025 sequentially, while Current Liabilities decreased, this led to improvement in Prf Technologies Ltd 's Quick Ratio to 2.22, Quick Ratio remained below Prf Technologies Ltd average.
Within Major Pharmaceutical Preparations industry 299 other companies have achieved higher Quick Ratio than Prf Technologies Ltd in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 1321, from total ranking in the third quarter 2025 at 1344.
PainReform s Public Offering Signals Growth in Clinical-Stage Pharmaceutical Industry In a recent announcement, PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, unveiled the pricing of its public offering, marking a significant milestone for the company s growth. The offering includes 5,000,000 of PainReform s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 5,000,000 ordinary shares, with a combined public offering price of $0.80 per share (or per ordinary share equivalent) and accompanying warrant. The decision to go public with this offering is a strategic move by PainReform to secure necessary funding for their ongoing initiatives in the reformulation of established therapeutics. The proceeds from the offering will support the company s clinical trials and the development of novel treatments, aiming to address unmet medical needs in various therapeutic areas.
PainReform Ltd Announces Exercise of Warrants, Garnering Approximately $1.3 Million in Gross Proceeds TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) PainReform Ltd (Nasdaq: PRFX), a leading clinical-stage specialty pharmaceutical company specializing in the reformulation of established therapeutics, has recently made a significant announcement. The company revealed the immediate exercise of certain outstanding warrants, enabling the purchase of up to 467,896 ordinary shares. These warrants were initially issued by PainReform in July 2023 and will now be exercised at a reduced price of $2.85 per ordinary share, as opposed to the original exercise price of $9.00 per share. The ordinary shares acquired through the exercise of warrants are registered under an effective registration statement on Form F-1 (File No. 333-274220). The completion of this offering is expected to take place around December 29, 2023, subject to the fulfillment of customary closing conditions.
On the trailing twelve months basis PRFX Cash & cash equivalent grew by 21.92 % in Q4 2025 year on year, while Current Liabilities fell to $2 millions, this led to increase in in Prf Technologies Ltd 's Quick Ratio to 1.81, Quick Ratio remained below PRFX average. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 371 other companies have achieved higher Quick Ratio than Prf Technologies Ltd . While Quick Ratio overall ranking has improved so far to 2915, from total ranking during the twelve months ending third quarter 2025 at 3502.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
